| The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings G Cavaletti, DR Cornblath, ISJ Merkies, TJ Postma, E Rossi, B Frigeni, ... Annals of Oncology 24 (2), 454-462, 2013 | 359 | 2013 |
| A vaccine targeting mutant IDH1 in newly diagnosed glioma M Platten, L Bunse, A Wick, T Bunse, L Le Cornet, I Harting, F Sahm, ... Nature 592 (7854), 463-468, 2021 | 332 | 2021 |
| Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin P Alberti, E Rossi, DR Cornblath, ISJ Merkies, TJ Postma, B Frigeni, ... Annals of oncology 25 (1), 257-264, 2014 | 187 | 2014 |
| Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patients J Frikkel, M Götte, M Beckmann, S Kasper, J Hense, M Teufel, M Schuler, ... BMC palliative care 19, 1-11, 2020 | 112 | 2020 |
| Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. P Meusers, J Hense, G Brittinger Leukemia (08876924) 11, 1997 | 80 | 1997 |
| MET expression in advanced non–small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy H Reis, M Metzenmacher, M Goetz, N Savvidou, K Darwiche, C Aigner, ... Clinical lung cancer 19 (4), e441-e463, 2018 | 77 | 2018 |
| 11C–MET PET/MRI for detection of recurrent glioma C Deuschl, J Kirchner, TD Poeppel, B Schaarschmidt, S Kebir, N El Hindy, ... European journal of nuclear medicine and molecular imaging 45, 593-601, 2018 | 75 | 2018 |
| Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution S Müller, P Schütt, P Bojko, MR Nowrousian, J Hense, S Seeber, T Moritz Annals of hematology 84, 110-114, 2005 | 72 | 2005 |
| High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer M Wiesweg, WEE Eberhardt, H Reis, S Ting, N Savvidou, C Skiba, ... Journal of Thoracic Oncology 12 (1), 54-64, 2017 | 70 | 2017 |
| Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma P Schütt, P Ebeling, U Buttkereit, D Brandhorst, B Opalka, M Hoiczyk, ... European journal of haematology 74 (1), 40-46, 2005 | 61 | 2005 |
| Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) D Binda, EK Vanhoutte, G Cavaletti, DR Cornblath, TJ Postma, B Frigeni, ... European journal of cancer 49 (13), 2910-2918, 2013 | 59 | 2013 |
| Correspondence between neurophysiological and clinical measurements of chemotherapy‐induced peripheral neuropathy: secondary analysis of data from the CI‐PeriNomS study KA Griffith, SG Dorsey, CL Renn, S Zhu, ME Johantgen, DR Cornblath, ... Journal of the Peripheral Nervous System 19 (2), 127-135, 2014 | 53 | 2014 |
| Enhanced immunoglobulin formation of immortalized B cells from hypertensive patients D Rosskopf, K Hartung, J Hense, W Siffert Hypertension 26 (3), 432-435, 1995 | 36 | 1995 |
| Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. UJ Vanhoefer, S Mayer, W Achterrath, J Hense, S Omidi, S Frings, ... ANNALS OF ONCOLOGY 11, 49-49, 2000 | 34 | 2000 |
| Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center M Wiesweg, S Ting, H Reis, K Worm, S Kasper, M Tewes, A Welt, H Richly, ... European Journal of Cancer 49 (15), 3076-3082, 2013 | 32 | 2013 |
| Patients' and physicians' interpretation of chemotherapy‐induced peripheral neurotoxicity G Cavaletti, DR Cornblath, ISJ Merkies, TJ Postma, E Rossi, P Alberti, ... Journal of the Peripheral Nervous System 24 (1), 111-119, 2019 | 31 | 2019 |
| Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer N Schleucher, M Tewes, W Achterrath, J Hense, S Omidi, S Frings, ... Proc Am Soc Clin Oncol 20, 141a, 2001 | 29 | 2001 |
| A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German … M Platten, D Schilling, L Bunse, A Wick, T Bunse, D Riehl, ... Journal of Clinical Oncology 36 (15_suppl), 2001-2001, 2018 | 27 | 2018 |
| Brief S2k guidelines–Merkel cell carcinoma JC Becker, C Assaf, D Vordermark, SN Reske, J Hense, T Dettenborn, ... JDDG: Journal der Deutschen Dermatologischen Gesellschaft 11 (s3), 29-36, 2013 | 27 | 2013 |
| Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide: case report and literature review N Hansen, A Wittig, J Hense, O Kastrup, ER Gizewski, JAP Van de Nes European Journal of Medical Research 16, 415-419, 2011 | 26 | 2011 |
